investig
potenti
adenoassoci
virus
serotyp
mediat
rna
interfer
rnai
antivir
agent
rabi
recombin
vector
express
sirna
target
nucleoprotein
n
gene
rabi
viru
rabv
construct
evalu
na
cell
pretreat
challeng
rabv
reduct
rabv
viru
titer
cell
prechalleng
rabv
treat
reduct
rabv
viru
titer
rel
quantif
rabv
transcript
use
realtim
pcr
western
blot
reveal
knockdown
rabvn
gene
transcript
base
inocul
titer
na
cell
treat
challeng
rabv
signific
reduct
viru
titer
observ
administr
mice
treat
intracerebr
exhibit
protect
challeng
intracerebr
intramusc
respect
lethal
rabv
mice
treat
intramuscularli
challeng
intramuscularli
lethal
rabv
exhibit
protect
mice
intracerebr
intramuscularli
hr
exposur
rabv
infect
exhibit
protect
n
gene
mrna
level
brain
challeng
mice
three
differ
administr
reduc
respect
result
indic
vectormedi
sirna
deliveri
vitro
na
cell
inhibit
rabv
multipl
inhibit
rabv
multipl
vivo
mice
brain
impart
partial
protect
lethal
rabi
may
potenti
use
altern
antivir
approach
rabi
rabi
diseas
central
nervou
system
constantli
produc
victim
human
be
well
anim
rabi
case
report
worldwid
preval
undevelop
countri
specif
rural
area
africa
asia
definit
effect
treatment
establish
cure
diseas
clinic
stage
reach
small
portion
clinic
case
respond
intens
therapeut
manag
surviv
clinic
symptom
rabi
appear
convent
postexposur
treatment
unsuccess
inabl
cross
bloodbrain
barrier
thu
current
strategi
control
rabi
preexposur
prophylaxi
vaccin
inject
research
effort
focus
develop
effect
safe
prophylact
andor
therapeut
tool
rabv
infect
rnai
mediat
small
interf
rna
sirna
power
technolog
allow
silenc
gene
great
specif
potenc
rnai
strategi
alreadi
success
appli
inhibit
replic
mani
virus
includ
hepat
b
viru
hbv
dengu
viru
dnv
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
sar
coronaviru
influenza
viru
consid
potenti
rnai
antivir
agent
group
evalu
rnaibas
antivir
agent
rabi
howev
one
potenti
limit
appli
technolog
develop
effect
target
deliveri
tool
viral
vector
one
major
vehicl
use
scientist
gene
therapi
get
sequenc
express
proper
host
viral
vector
includ
adenoviru
retroviru
lentiviru
adenoassoci
viru
aav
undoubtedli
effici
tool
gene
deliveri
wide
use
deliv
variou
gene
sirna
recent
gupta
et
al
sonwan
et
al
report
adenovir
vectormedi
deliveri
small
hairpin
sh
rna
target
rabv
n
polymeras
l
mrna
led
slight
increas
surviv
rabvinfect
mice
far
research
group
report
whether
aav
work
sirna
deliveri
tool
transport
sirna
target
rabv
cell
host
inhibit
rabv
replic
studi
construct
recombin
aav
vector
base
serotyp
express
sirna
target
n
gene
rabv
vitro
vivo
experi
could
effici
inhibit
replic
rabv
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
hyclon
logan
ut
usa
rabv
viru
standard
cv
strain
obtain
changchun
institut
veterinari
scienc
changchun
china
femal
balbc
mice
weigh
g
changchun
institut
biolog
product
changchun
china
use
assess
antivir
activ
vivo
experi
rabv
viru
conduct
biosafeti
level
three
laboratori
facil
changchun
institut
veterinari
scienc
plasmid
construct
paavhrgfp
paavrc
phelper
describ
inform
provid
aav
helperfre
system
catalog
agil
technolog
santa
clara
ca
usa
target
n
gene
insert
hygro
sirna
express
vector
ambion
austin
tx
usa
bamhi
hindiii
plasmid
transport
liposom
could
inhibit
rabv
replic
vitro
vivo
sirna
express
box
contain
cmv
cgfp
promot
sirna
amplifi
noti
introduc
sirnaexpress
box
digest
noti
insert
paavhrgfp
treat
noti
neg
control
name
paavneg
encod
specif
shrna
shown
fig
aav
vector
product
raavneg
vector
produc
liposomemedi
cotransfect
paavneg
paavrc
phelper
human
embryon
kidney
hek
cell
accord
protocol
briefli
hr
transfect
plate
human
cell
confluent
fed
ml
fresh
dmem
contain
fb
without
antibiot
total
mg
plasmid
dna
dissolv
ml
liposom
invitrogen
carlsbad
ca
usa
mix
ad
cell
incub
min
hr
transfect
medium
replac
fresh
dmem
contain
fb
antibiot
cell
suspens
harvest
hr
post
infect
lowspe
centrifug
tabletop
centrifug
cell
pellet
resuspend
ml
mm
mm
trishcl
ph
subject
four
cycl
freezethaw
remov
cell
debri
raav
particl
transduct
raav
infect
rabv
na
cell
na
cell
plate
cellswel
plate
incub
overnight
raav
inocul
cell
differ
viral
titer
transduct
hr
medium
replac
fresh
dmem
contain
fb
antibiot
hr
transduct
cell
infect
moi
rabv
viru
hr
anoth
method
infect
cell
moi
rabv
viru
hr
inocul
raav
viral
titer
assay
viral
titer
measur
use
tissu
cultur
infect
dose
tcid
assay
serial
dilut
supernat
treat
viral
sampl
ad
onto
monolay
cell
cultur
plate
incub
two
day
viru
concentr
measur
direct
fluoresc
antibodi
stain
dfa
describ
viral
titer
sampl
calcul
reedmuench
method
realtim
pcr
na
cell
mous
brain
harvest
rabv
infect
total
rna
extract
use
trizol
reagent
invitrogen
accord
manufactur
instruct
rna
revers
transcrib
cdna
use
amv
revers
transcriptas
promega
madison
wi
usa
level
n
mrna
transcript
determin
qpcr
use
brilliant
ii
sybr
green
qpcr
master
mix
stratagen
la
jolla
ca
usa
follow
genespecif
primer
forward
primer
genom
revers
primer
genom
bp
amplicon
forward
primer
revers
primer
bp
amplicon
pcr
carri
mx
system
rel
express
valu
n
gene
normal
express
valu
gene
western
blot
na
cell
harvest
hr
rabv
infect
total
protein
sampl
obtain
incub
cell
lysi
buffer
beyotim
biotech
inc
nantong
china
protein
concentr
measur
bicinchonin
acid
bca
protein
assay
pierc
rockford
il
usa
fifti
microgram
aliquot
total
protein
resolv
sodium
sdspage
transfer
nitrocellulos
membran
amersham
bioscienc
uppsala
sweden
result
blot
probe
mous
monoclon
antibodi
rabv
n
protein
mous
monoclon
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
usa
follow
horseradish
peroxidaseconjug
goat
antimous
igg
santa
cruz
biotechnolog
immunoreact
band
detect
enhanc
chemiluminesc
reagent
pierc
viral
challeng
mice
mice
group
eleven
anesthet
dri
ice
inocul
intracerebr
intramuscularli
masset
muscl
raav
itr
sirna
transcript
produc
promot
cgfp
transcript
produc
cmv
promot
cmv
ie
enhanc
promot
cmv
promot
vgkg
mice
infect
ld
rabv
intracerebr
challeng
ld
rabv
intramuscular
challeng
inocul
site
raav
inocul
site
third
group
mice
inocul
intracerebr
raav
challeng
ld
rabv
intramuscularli
masset
muscl
hr
inocul
raav
vgkg
forth
group
mice
infect
rabv
intramuscularli
inocul
raavneg
intracerebr
intramuscularli
infect
hr
day
post
infect
rabv
three
mice
group
anesthet
brain
collect
assay
viru
titer
mice
observ
day
surviv
anim
research
conduct
guidanc
cdc
institut
anim
care
use
committe
associ
assess
accredit
laboratori
anim
care
internationalaccredit
facil
anim
research
studi
approv
jilin
provinc
anim
diseas
control
center
statist
analysi
statist
signific
differ
experiment
group
determin
use
pair
nonparametr
student
ttest
p
consid
signific
differ
evalu
antivir
effect
target
conserv
sequenc
gene
neg
control
raavneg
respect
inocul
na
cell
vgcell
transduct
effici
raav
na
cell
result
shown
transduct
hr
cell
infect
moi
rabv
viru
differ
time
point
cell
supernat
collect
analysi
rabv
titer
shown
fig
viru
titer
group
significantli
lower
p
raavneg
group
time
point
hr
post
infect
viru
titer
tcid
ml
pretreat
group
reduc
nearli
time
p
compar
raavneg
group
tcid
ml
rabv
infect
raav
transduct
signific
differ
observ
hr
post
infect
hr
post
infect
fig
rabv
titer
reduc
significantli
p
result
indic
inocul
rabv
infect
could
inhibit
viru
replic
well
inocul
rabv
infect
inhibit
viru
replic
later
time
point
check
whether
antivir
activ
na
cell
depend
inocul
titer
show
fig
na
cell
transduc
differ
titer
vgcell
infect
moi
rabv
viru
transduct
hr
hr
post
infect
cell
collect
assay
n
gene
mrna
level
protein
level
result
show
n
gene
mrna
level
reduc
respect
compar
raavneg
group
na
cell
infect
rabv
firstli
transduc
differ
titer
vgcell
fig
signific
lower
n
gene
mrna
level
p
observ
higher
titer
group
vgcell
lower
titer
group
vgcell
n
protein
level
also
show
similar
result
higher
titer
lower
n
protein
level
indic
antivir
activ
na
cell
depend
titer
collect
result
demonstr
could
significantli
inhibit
replic
viru
na
cell
antivir
activ
pretreat
better
treatment
infect
test
whether
inhibit
rabv
replic
observ
vitro
adequ
protect
vivo
use
establish
balbc
mous
model
rabv
test
whether
could
protect
mice
rabv
infect
brain
shown
fig
mice
first
intracerebr
treat
intracerebr
challeng
lethal
dose
ld
hr
later
compar
raavnegtr
mice
mice
show
fewer
clinic
sign
diseas
lower
morbid
moreov
mous
surviv
rate
group
show
higher
surviv
rate
raavnegtr
mice
day
postchalleng
mous
surviv
rate
group
mice
raavnegtr
group
die
day
postchalleng
test
whether
could
protect
mice
rabv
infect
masset
muscl
shown
fig
mice
intramuscularli
treat
intramuscularli
challeng
lethal
dose
ld
rabv
hr
later
result
show
partial
protect
virul
rabv
challeng
mice
pretreat
protect
mice
pretreat
raavneg
check
whether
intracerebr
inocul
could
protect
mice
intramuscular
infect
rabv
shown
fig
mice
first
intracerebr
treat
intramuscularli
challeng
lethal
dose
ld
rabv
hr
later
treatment
mice
demonstr
protect
mice
treat
raavneg
die
day
postchalleng
mice
surviv
develop
symptom
remain
healthi
entir
period
experiment
moreov
day
post
challeng
check
n
gene
mrna
level
brain
three
administr
result
show
fig
n
gene
mrna
level
mice
brain
significantli
decreas
also
n
gene
mrna
level
intracerebr
pretreat
group
lower
intramuscular
pretreat
group
agre
result
pertain
mous
surviv
rate
postexposur
vaccin
obligatori
case
treatment
human
exposur
infect
anim
bite
regard
whether
could
protect
mice
expos
rabv
infect
within
hr
mice
first
intramuscularli
challeng
lethal
dose
ld
rabv
inject
intracerebr
intramuscularli
hr
later
result
fig
show
partial
protect
protect
mice
treat
raavneg
n
gene
mrna
level
mous
brain
significantli
decreas
compar
control
fig
result
provid
evid
treatment
could
inhibit
rabv
replic
confer
partial
protect
lethal
rabi
challeng
rabi
one
oldest
fatal
viral
diseas
known
mankind
clinic
rabi
viru
invad
central
nervou
system
incur
need
develop
effect
antirabi
approach
rna
interfer
rnai
emerg
potenti
therapeut
strategi
suppress
viru
replic
vitro
vivo
without
damag
host
cell
howev
one
potenti
limit
appli
technolog
develop
effect
target
deliveri
tool
studi
develop
univers
sirna
agent
would
recogn
differ
rabv
strain
use
n
gene
highli
conserv
gene
among
five
rabv
gene
moreov
select
conserv
sequenc
n
transcript
use
rnai
target
wide
use
deliv
variou
gene
sirna
viral
vector
could
stimul
host
immun
respons
produc
specif
antibodi
viral
vector
would
restrict
use
host
addit
unwant
activ
immun
respons
safeti
concern
also
involv
offtarget
effect
aav
vector
highli
success
overcom
disadvantag
current
among
frequent
use
viral
vector
gene
therapi
twelv
human
serotyp
aav
serotyp
nonhuman
primat
discov
date
character
new
aav
serotyp
reveal
differ
pattern
transduct
divers
tissu
aav
becom
increasingli
common
vector
use
human
clinic
trial
immunodefici
diseas
muscl
direct
gene
therapi
lung
diseas
raav
vector
transduc
muscl
liver
brain
retina
lung
emerg
vector
choic
gene
transfer
central
nervou
system
strong
neuron
tropism
lack
pathogen
mammal
moreov
shown
induc
weak
cellmedi
immun
respons
may
attribut
aav
ineffici
infect
matur
dendrit
cell
dc
studi
made
use
vector
deliv
sirna
target
rabv
n
gene
result
vitro
na
cell
vivo
mice
brain
muscl
experi
show
work
good
sirna
deliveri
tool
genom
linear
singlestrand
dna
kb
infect
secondstrand
synthesi
need
gene
express
time
would
later
doublestrand
dna
viru
vector
vitro
experi
treatment
later
rabv
infect
antivir
effect
display
hr
post
infect
display
hr
post
infect
fig
reason
may
ascrib
later
gene
express
synthes
secondstrand
shrna
begin
transcrib
promot
time
secondstrand
synthesi
replic
rabv
inhibit
viru
replic
sever
cycl
rabv
titer
raavneg
treatment
group
increas
effici
antivir
effect
observ
earli
infect
clinic
rabi
cn
form
diseas
treat
antirabi
rnai
elimin
rabv
infect
neuron
deliv
antirabi
sirna
effect
neuron
emerg
vector
choic
gene
transfer
central
nervou
system
vivo
experi
antivir
effect
intracerebr
inocul
surviv
respect
better
intramuscular
inocul
surviv
whether
transduct
effici
muscl
higher
brain
need
investig
surviv
rate
intracerebr
inocul
infect
group
surviv
lower
intracerebr
inocul
intramuscular
infect
group
surviv
infect
rabv
time
symptom
shown
associ
site
infect
rabv
introduc
skin
mucou
membran
replic
myocyt
hour
week
migrat
nerv
rabv
introduc
brain
would
replic
quickli
process
rabv
entri
brain
masset
muscl
time
transduc
neural
cell
produc
sirna
direct
intracerebr
infect
antivir
effect
intracerebr
inocul
intramuscular
infect
better
intracerebr
inocul
infect
antivir
activ
present
exposur
rabv
infect
hr
later
howev
antivir
activ
would
lost
mice
inject
show
symptom
data
shown
retain
antivir
activ
exposur
rabv
infect
time
inject
within
hr
antivir
activ
na
cell
depend
titer
vivo
experi
pretreat
achiev
complet
protect
may
associ
inocul
dose
biggest
raav
titer
achiev
lab
cotransfect
cell
vgml
better
method
produc
raav
particl
need
establish
product
raav
vector
insect
cell
via
use
recombin
baculoviru
technolog
proven
effici
scalabl
mean
raav
product
yield
genomecontain
particl
produc
per
cell
approach
thu
ml
cultur
cell
produc
equival
cm
flask
cell
robust
system
provid
simpl
costeffect
method
aav
vector
product
howev
achiev
complet
protect
sirna
target
rabv
gene
raav
titer
time
therapeut
administr
assess
gener
optim
treatment
strategi
